Regulation of Lipid and Lipoprotein Metabolism by PPAR Activators

Clinical Chemistry and Laboratory Medicine - Tập 38 Số 1 - Trang 3-11 - 2000
Philippe Gervois1, Inés Pineda‐Torra, Jean‐Charles Fruchart, Bart Staels
1Département d'Athérosclérose, INSERM U.325, Institut Pasteur de Lille et Faculté de Pharmacie, Université de Lille II, France.

Tóm tắt

Abstract The peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors belonging to the nuclear hormone receptor superfamily. PPARα, the first identified PPAR family member, is principally expressed in tissues exhibiting high rates of β-oxidation such as liver, kidney, heart and muscle. PPARγ, on the other hand, is expressed at high levels in adipose tissue. PPARs are activated by dietary fatty acids and eicosanoids, as well as by pharmacological drugs, such as fibrates for PPARα and glitazones for PPARγ. PPARα mediates the hypolipidemic action of fibrates in the treatment of hypertriglyceridemia and hypoalphalipoproteinemia. PPARα is considered a major regulator of intra- and extracellular lipid metabolism. Upon fibrate activation, PPARα down-regulates hepatic apolipoprotein C-III and increases lipoprotein lipase gene expression, key players in triglyceride metabolism. In addition, PPARα activation increases plasma HDL cholesterol via the induction of hepatic apolipoprotein A-I and apolipoprotein A-II expression in humans. Glitazones exert a hypotriglyceridemic action via PPARγ-mediated induction of lipoprotein lipase expression in adipose tissue. PPARs play also a role in intracellular lipid metabolism by up-regulating the expression of enzymes involved in conversion of fatty acids in acyl-coenzyme A esters, fatty acid entry into mitochondria and peroxisomal and mitochondrial fatty acid catabolism. These observations have provided the molecular basis leading to a better understanding of the mechanism of action of fibrates and glitazones on lipid and lipoprotein metabolism and identify PPARs as attractive targets for the rational design of more potent lipid-lowering drugs.

Từ khóa


Tài liệu tham khảo

10.1016/S0140-6736(94)90566-5

10.1056/NEJM199511163332001

10.1016/S0735-1097(98)00560-9

Haim M, 1999, Circulation, 100, 475, 10.1161/01.CIR.100.5.475

Staels B, 1998, Circulation, 98, 2088, 10.1161/01.CIR.98.19.2088

10.1016/S0140-6736(96)91343-4

Frick MH, 1997, Circulation, 96, 2137, 10.1161/01.CIR.96.7.2137

10.1056/NEJM199908053410604

Reddy J, 1979, Br J Cancer, 40, 476, 10.1038/bjc.1979.203

10.1038/347645a0

Vanden Heuvel JP, 1999, J Nutr, 129, 575S, 10.1093/jn/129.2.575S

Lee SS, 1995, Mol Cell Biol, 15, 3012, 10.1128/MCB.15.6.3012

Schoonjans K, 1996, Biochim Biophys Acta, 1302, 93, 10.1016/0005-2760(96)00066-5

Cullingford TE, 1998, J Neurochem, 70, 1366, 10.1046/j.1471-4159.1998.70041366.x

10.1210/en.137.1.354

10.2337/diabetes.46.8.1319

10.1016/0092-8674(92)90031-7

10.1210/en.139.6.2748

10.2337/diabetes.47.4.507

10.1016/S1097-2765(00)80047-7

10.1038/2036

10.1038/2042

10.1038/2030

10.1016/S1367-5931(97)80015-4

10.1016/S0092-8674(00)81574-3

10.1016/S1097-2765(00)80467-0

10.1074/jbc.274.10.6718

10.1210/me.13.3.400

10.1038/31701

10.1038/34178

10.1038/35154

Sakai M, 1995, Cancer Res, 53, 5370

Delerive P, 1999, Circ Res, 85, 394, 10.1161/01.RES.85.5.394

10.1074/jbc.274.45.32048

Lemberger T, 1994, J Biol Chem, 269, 24527, 10.1016/S0021-9258(17)31420-5

10.1111/j.1432-1033.1994.0967b.x

10.1074/jbc.274.25.17541

10.1073/pnas.96.5.2391

10.1172/JCI6223

10.1074/jbc.271.3.1764

10.1210/me.13.9.1535

Palmer CN, 1998, Mol Pharmacol, 53, 14, 10.1124/mol.53.1.14

10.1073/pnas.92.17.7921

10.1074/jbc.272.30.18779

10.1074/jbc.272.32.20230

Wu Z, 1996, Mol Cell Biol, 16, 4128, 10.1128/MCB.16.8.4128

10.1074/jbc.274.15.10505

10.1038/24634

10.1210/en.137.10.4499

10.1074/jbc.272.43.27295

10.1126/science.274.5295.2100

10.1210/en.140.1.392

10.1074/jbc.274.27.19228

10.1074/jbc.274.22.15775

10.1074/jbc.273.10.5678

10.1074/jbc.272.45.28210

10.1074/jbc.273.27.16710

10.1074/jbc.273.15.8560

10.1074/jbc.273.37.23786

10.1074/jbc.273.49.32901

10.1172/JCI3949

10.1073/pnas.96.13.7473

10.1210/en.139.12.4920

10.2337/diabetes.48.6.1217

10.1006/bbrc.1999.0555

10.1101/gad.8.10.1224

Tontonoz P, 1995, Mol Cell Biol, 15, 351, 10.1128/MCB.15.1.351

10.1074/jbc.270.33.19269

10.1111/j.1432-1033.1993.tb18181.x

Schoonjans K, 1996, EMBO J, 15, 5336, 10.1002/j.1460-2075.1996.tb00918.x

10.1007/BF00544015

10.1016/0021-9150(89)90075-0

10.1172/JCI107904

Caslake MJ, 1993, Arterioscler Thromb, 13, 702, 10.1161/01.ATV.13.5.702

10.1172/JCI118118

Vu-Dac N, 1994, J Biol Chem, 269, 31012, 10.1016/S0021-9258(18)47383-8

10.1172/JCI118687

10.2337/diabetes.39.10.1218

10.1021/jm00092a012

10.2337/diabetes.43.2.204

10.2337/diabetes.44.9.1087

10.1021/jm970444e

10.1021/jm9805541

Lefebvre AM, 1997, Arterioscler Thromb Vasc Biol, 17, 1756, 10.1161/01.ATV.17.9.1756

Hertz R, 1995, J Biol Chem, 270, 13470, 10.1074/jbc.270.22.13470

10.1172/JCI117717

10.1074/jbc.272.43.27307

Ladias JA, 1992, J Biol Chem, 267, 15849, 10.1016/S0021-9258(19)49613-0

10.1172/JCI1581

10.1074/jbc.273.40.25713

Duez H, 1998, Circulation, 98, 2363, 10.1161/01.CIR.98.22.2363

10.1074/jbc.273.49.32833

10.1074/jbc.274.5.2672

10.1016/S0140-6736(75)92376-4

10.2165/00003495-199040040-00006

10.1016/0021-9150(85)90095-4

10.1016/0026-0495(92)90208-R

10.1111/j.1432-1033.1995.tb20797.x

10.1074/jbc.273.45.29577

Hennuyer N, 1999, Circulation, 99, 2445, 10.1161/01.CIR.99.18.2445

Staels B, 1992, Arterioscler Thromb, 12, 286, 10.1161/01.ATV.12.3.286

Staels B, 1992, Biochim Biophys Acta, 1123, 227, 10.1016/0005-2760(92)90115-C

Staels B, 1992, J Lipid Res, 33, 727, 10.1016/S0022-2275(20)41436-1

10.1126/science.271.5248.518

Calvo D, 1997, Arterioscler Thromb Vasc Biol, 17, 2341, 10.1161/01.ATV.17.11.2341

10.1074/jbc.272.34.20982

10.1073/pnas.96.16.9322

10.1074/jbc.273.40.25573

10.1016/S0021-9150(99)80435-3

Thông tin
Thông tin xuất bản

Clinical Chemistry and Laboratory Medicine

Tập 38 Số 1

3-11

Thông tin tác giả